慢性阻塞性肺疾病的免疫治疗进展

Progress in immunotherapy of chronic obstructive pulmonary disease

目前慢性阻塞性肺疾病（chronic obstructive pulmonary disease，COPD）治疗仍以糖皮质激素，支气管扩张剂，以及其他全身并发症的对症治疗为主，但其均不能减缓COPD进行性发展。随着对发病机制的深入研究发现，COPD肺内T细胞异常激活，CD4^＋／CD8^＋比值倒置，并出现各种针对气道内皮抗体，即使去除各种诱因后，病变仍持续存在，同时COPD患者多合并免疫功能下降和（或）其他自身免疫性疾病，提示了免疫机制在该病发病及进展中的作用。现就COPD的免疫治疗作一综述。

Therapies of chronic obstructive pulmonary disease （COPD）mainly were based on eorticosteroid,bronchodilators and other systemic complications symptomatic treatments currently,but all cannot relieve progress. With cleep studying of pathogenesis, it was found that T cell abnormally was activated and CD4^＋/CD8^＋ ratio was inversed in lung,moreover a variety of antibodies against endothelial cells of airway was presented, although all incentives were eliminated, the procession still went on. Declined immunity function and （or）other autoimmune disease in COPD patients suggested immune mechanisms have a role in pathogenesis and progress. Now immunotherapy are reviewed.